Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
52 results about "Integrin Receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
And around the cell, integrins and is mediated transmembrane receptor binding between the extracellular matrix or other cells of the (ECM). It is integrin signaling for transmitting information about the mechanical state of the ECM in the cell and chemical composition.
Bioactive stents for type II diabetics and methods for use thereof
InactiveUS20060013855A1StentsImmunoglobulins against cell receptors/antigens/surface-determinantsProgenitorBlood vessel
The present invention is based on the discovery that a vascular stent or other implantable medical device can be coated with a biodegradable biocompatible polymer to which is attached a bioligand that specifically captures progenitors of endothelial cells (PECs) from the circulating blood to promote endogenous formation of healthy endothelium in Type II diabetics. In one embodiment, the bioligand is a peptide that specifically binds to an integrin receptor on PECs. The invention also provides methods for using such vascular stents and other implantable devices to promote vascular healing in Type II diabetics, for example following mechanical intervention.
Owner:MEDIVAS LLC
Bioactive stents for type II diabetics and methods for use thereof
The present invention is based on the discovery that a vascular stent or other implantable medical device can be coated with a biodegradable biocompatible polymer to which is attached a bioligand that specifically captures progenitors of endothelial cells (PECs) from the circulating blood to promote endogenous formation of healthy endothelium in Type II diabetics. In one embodiment, the bioligand is a peptide that specifically binds to an integrin receptor on PECs. The invention also provides methods for using such vascular stents and other implantable devices to promote vascular healing in Type II diabetics, for example following mechanical intervention.
Owner:MEDIVAS LLC
Delivery system for nucleic acids
Owner:THE SCRIPPS RES INST +1
Anti-alpha v immunoliposome compositions, methods and uses
InactiveUS20110268655A1Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsInternalizationTargeting ligands
An immunoliposome composition targeted to the alphaV-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha V subunit including αvβ1, αvβ3 αvβ5, αvβ6, or αvβ8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab′ fragment, a scFv, or the like. Binding of the immunoliposome to αv-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent.
Owner:CENTOCOR ORTHO BIOTECH
Symmetrical difunctional coupling agent and coupled molecular imaging agents thereof
InactiveCN102391168ASolve coupling problemsSolving Difficult-to-Separate PuzzlesIn-vivo radioactive preparationsHybrid peptidesPharmacophoreGastrin-releasing peptide receptor
The invention provides a symmetrical difunctional coupling agent compound (I), i.e. N-fluorenylmethyloxycarbonyl-L-beta-glutamate-di-N-succinimide (Fmoc-beta-Glu(OSu)-OSu), and a production method thereof. Based on the compound, a series of novel coupling compounds which respectively contain a symmetrical difunctional coupling base, i.e. beta-Glu (beta-glutamate) are prepared through being coupled to ligand molecules; the structural formula of the series of coupling compounds is shown as (II), wherein M1 is a -NH2-contained ligand of a target molecule T1, M2 is a -NH2-contained ligand of a target molecule T2, L is a linking group, and S is a report signal group. The compound (1) provided by the invention has been used in coupling a targeted integrin alphavbeta3 receptor ligands, gastrin-releasing peptide receptor ligands, telomerase inhibitor pharmacophores and epidermal growth factor receptor ligands, and thus, a plurality of coupled bi-ligand molecular imaging agents and coupled tri-ligand molecular imaging agents are synthesized. The invention further relates to the use of the compound (I) and the series of novel coupling compounds (II) in the preparation of imaging agent drugs.
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
Bioactive Stents For Type II Diabetics and Methods for Use Thereof
The present invention is based on the discovery that a vascular stent or other implantable medical device can be coated with a biodegradable biocompatible polymer to which is attached a bioligand that specifically captures progenitors of endothelial cells (PECs) from the circulating blood to promote endogenous formation of healthy endothelium in Type II diabetics. In one embodiment, the bioligand is a peptide that specifically binds to an integrin receptor on PECs. The invention also provides methods for using such vascular stents and other implantable devices to promote vascular healing in Type II diabetics, for example following mechanical intervention.
Owner:MEDIVAS LLC
Bioactive stents for type ii diabetics and methods for use thereof
InactiveUS20110137406A1StentsImmunoglobulins against cell receptors/antigens/surface-determinantsProgenitorBlood vessel
The present invention is based on the discovery that a vascular stent or other implantable medical device can be coated with a biodegradable biocompatible polymer to which is attached a bioligand that specifically captures progenitors of endothelial cells (PECs) from the circulating blood to promote endogenous formation of healthy endothelium in Type II diabetics. In one embodiment, the bioligand is a peptide that specifically binds to an integrin receptor on PECs. The invention also provides methods for using such vascular stents and other implantable devices to promote vascular healing in Type II diabetics, for example following mechanical intervention.
Owner:MEDIVAS LLC
Double receptor identified serial cell-penetrating peptide modified tumor targeted nano drug delivery system
The invention provides a serial cell-penetrating peptide modified tumor targeted and tumor penetrated nano drug delivery system capable of simultaneously identifying an integrin receptor and a transmembrane protein receptor, wherein the serial cell-penetrating peptide is mainly formed by connecting a DGR polypeptide fragment covalently at the C-tail end of polyarginine of the cell-penetrating peptide. The polypeptide not only can selectively identify two highly expressed receptors on the surfaces of the tumor cells, but also can be efficiently mediated into the cells. The nano drug delivery system mainly consists of a nano carrier, a drug and a lipid-polyethylene glycol-serial cell-penetrating peptide ligand interstitial compound and is a potential tumor targeted treatment carrier.
Owner:SICHUAN UNIV
USPIO-PLA-RGD compound, preparation method and application thereof
InactiveCN101590245AIncrease concentrationTo achieve the purpose of live imagingNMR/MRI constrast preparationsTumor angiogenesisSide effect
The invention discloses a USPIO-PLA-RGD compound, a preparation method and application thereof. The USPIO-PLA-RGD compound uses USPIO as a core, is coated by PLA outside, and is labeled as PLA-USPIO; and the USPIO-PLA-GRD compound obtained through covalently coupling carboxyl of a functional group exposed on the surface of PLA and amidogen of RGD peptide has a hydrated grain diameter of between 90 and 105 nm. The USPIO-PLA-RGD compound can be applied as magnetic resonance tumor angiogenesis targeting contrast agent. The invention realizes targeting developing by the characteristics of high affinity of an alpha v beta3 integrin receptor and ligand RGD peptide thereof, and the combination has the characteristics of high specificity, selectivity, saturation and affinity, clear biological effect and the like. The concentration of a medicament in a partial focus can be increased, and toxic and side effects can be reduced by using the ligand RGD peptide as a vector of USPIO through the mediation effect of the receptor, so that the aim of development of a targeting tumor angiogenesis living body is realized.
Owner:ZHEJIANG UNIV
Antibody of human origin for inhibiting thrombocytes aggregation
InactiveUS20110165175A1Improve propertiesEasy to understandImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsIntegrin ReceptorPlatelet inhibition
Owner:AFFIMED THERAPEUTICS
Cyclic NGR polypeptide, radionuclide labeled molecular probe and application thereof
ActiveCN112079900ARealize the purpose of videoImprove targetingRadioactive preparation carriersPeptide preparation methodsIn vivoStructural formula
The invention provides a cyclic NGR polypeptide, a radionuclide-labeled aminopeptidase targeting molecular probe and application thereof. The molecular probe is obtained by labeling the cyclic NGR polypeptide with radionuclide, or coupling the cyclic NGR polypeptide with a bifunctional chelating group, and then labeling the coupled product with radionuclide. The radionuclide-labeled aminopeptidasetargeting molecular probe can be used for preparing a developing agent for diagnosing aminopeptidase N (CD13) high-expression tumors or preparing a drug for biological targeting treatment of aminopeptidase N (CD13) high-expression tumors. The integrin receptor can be accurately positioned in vivo, the aim of tumor molecular imaging is achieved through nuclear medicine imaging, and the in-vivo targeting property and the retention time thereof can be remarkably improved. And the aminopeptidase N (CD13) tumor can be accurately positioned as a carrier of radioactive therapy nuclide, so that the aim of treating tumors is fulfilled. The structural formula of the cyclic NGR polypeptide is shown in the specification.
Owner:INST OF NUCLEAR PHYSICS & CHEM CHINA ACADEMY OF
Vitronectin:keratinocyte growth factor chimeras
InactiveUS9562086B2Easy to producePeptide/protein ingredientsAntibody mimetics/scaffoldsCancer cellProtein-protein complex
Isolated protein complexes are provided comprising keratinocyte growth factor and vitronectin, or at least domains thereof that enable binding to and activation of both a keratinocyte growth factor receptor and an integrin receptor for vitronectin. These protein complexes include synthetic proteins where the keratinocyte growth factor and vitronectin sequences are joined by a linker sequence. In particular forms, vitronectin sequences do not include a C-terminal heparin binding domain. Also provided are uses of these protein complexes for stimulating or inducing cell migration and / or proliferation in wound healing, tissue engineering, cosmetic and therapeutic treatments such as skin replacement, skin replenishment and treatment of burns where epithelial cell migration is required. In other embodiments, the invention provides inhibition of cancer cell metastasis, particularly in relation to breast cancer.
Owner:FACTOR THERAPEUTICS LTD
Preparation method of SPECT/CT (Single Photon Emission Computed Tomography/Computed Tomography) dual-mode imaging contrast agent based on second-generation polyamide-amine dendritic polymer
InactiveCN107281504AImprove performanceRealize requirementsGeneral/multifunctional contrast agentsRadioactive preparation carriersDual modeArginine
The invention relates to a preparation method of SPECT / CT (Single Photon Emission Computed Tomography / Computed Tomography) dual-mode imaging contrast agent based on a second-generation polyamide-amine dendritic polymer. The method comprises the following steps: by taking the second-generation polyamide-amine dendritic polymer as a template material, sequentially modifying a radionuclide 99mTc chelating agent NOTA and a pegylated RGD (Arginine-Glycin-Aspartate) molecule on the surface; coating gold nanoparticles through an in-situ reduction synthesis method; and finally, labeling the radionuclide 99mTc, thereby obtaining the product. The SPECT / CT contrast agent prepared by the method disclosed by the invention has excellent colloidal stability, excellent biocompatibility, long blood circulation time and excellent in-vitro / vitro SPECT / CT imaging effect, has a specific targeting effect on C6 cells of an alphavbeta3 integrin receptor on the cell membrane surface and provides a good thought for developing a novel dual-mode nano contrast agent.
Owner:DONGHUA UNIV +1
Cyclic peptide containing arginine, glycine, asparagicacid-sequence and active target liposome
InactiveCN1687118ASmall molecular weightEasy to retouchDigestive systemPeptidesArginineTherapeutic effect
The present invention belongs to the field of pharmaceutical technology and clinical pharmacy, relates to a cyclopeptide containing arginine-glycine-aspartic acid (RGD) sequence and its active liposome targeting, its preparation and application. The described cyclopeptide structure meets the requirements as ligand, and is cyclized by amido bond, its spatial conformation is stable, and is not easily degraded, its one end contains active sulphydryl group, and is convenient for modifying artificially-synthetic function peptide, its molecular weight is small, so that it is not easy to result in immune reaction, and can be used as ligand, and can be combined with hepatic stellate cell (HSC) surface integrator acceptor to construct active liposome targeting and implement target therapy for experimental hepatic fibroid cell. Said invention can obtain good therapeutic effect for curing hepatitis fibrosis.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV +1
Oriented collagen gel
ActiveUS20100227043A1Reduce porosityPeptide/protein ingredientsPharmaceutical containersFiberIn vivo
Techniques for the production of flow-oriented collagen gels using hydrodynamics to influence the assembly of collagen fibers. Highly concentrated monomeric solutions of collagen are subjected to shear and extensional flow as they are drawn onto a substrate to induce fibrillogenesis under a high Ph buffer. The produced gel captures the flow induced ordering of molecular collagen upon fibril formation. The depositing or the induction of fibrillogenosis occurs without the application of a magnetic field to the concentration of collagen. These highly oriented 3D scaffolds are capable inducing contact guidance and guiding mammalian cell growth. The collagen fibers mimic the construction of in vivo fibers with the characteristic D-periodicity and the integrin receptors on the fibroblasts respond to this organization. The industrial applications of three-dimensional collagen gels as a biomaterial are widespread from drug delivery to burn repair or tissue engineering system.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
InactiveUS20090196913A1Inhibit growthPrevent proliferationBiocideCarbohydrate active ingredientsIntegrin ReceptorCytoplasm
An immunoliposome composition targeted to the alpha-V-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha-V subunit including αvβ1, αvβ3 αvβ5, αvβ6, or αvβ8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab′ fragment, a scFv, or a the like. Binding of the immunoliposome to αv-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent.
Owner:HUANG KEN SHI KUN +3
Near-infrared fluorescent probe targeting tumor cells and activated by beta-galactosidase and preparation method thereof
InactiveCN110845556AHigh fluorescence intensityEasy to detectSugar derivativesFluorescence/phosphorescenceCancers diagnosisFluorophore
The invention discloses a preparation method of a near-infrared fluorescent compound which accurately targets tumor cells and is activated by beta-galactosidase, wherein the structure of the fluorescent compound is shown in a formula I. The probe compound combines a substrate alphaD-galactose (alphaD-gal) recognized by beta-galactosidase with cyanine near-infrared fluorophores to introduce an alphavbeta3-integrin receptor-targeted ligand c-RGD. The ability of the ligand c-RGD targeting tumor cells is utilized for near-infrared imaging of live mouse tumors overexpressing beta-galactosidase. Theprobe has the advantages that receptor-mediated cell uptake and molecular target activation are combined to realize real-time and non-invasive detection of beta-galactosidase in living tissues. The probe can be successfully applied to improve cancer imaging and promote effective cancer diagnosis.
Owner:UNIV OF JINAN
Amino cyanine fluorescent dyes and preparation method therefor and application thereof
InactiveCN105111773AGood application effectWith characteristicsMethine/polymethine dyesFluorescence/phosphorescenceStructural formulaAlpha-v beta-3
The invention discloses amino cyanine fluorescent dyes connected with cyclopeptide [cyclo(RGD)] and a preparation method therefor and application thereof. The structural formula of the compounds is shown in I. The compounds consist of structural units III and III; the structural unit II is a derived cyanine dye structure which is water soluble fluorescent molecules, the spectrum of which has relatively great Stokes shift, and the molecules have relatively less toxicity to normal cells; the structural unit III is a cyclopeptide structure of a specific ligand of an alpha v beta 3 integrin receptor and can be used for targeted orientation. The fluorescent dyes have the double function characteristic of tumor imaging diagnosis and targeted therapy.
Owner:DALIAN UNIV OF TECH
Integrin receptor-targeted taxol nanocomposite and preparation method thereof
InactiveCN102836436AIncrease drug concentrationImprove therapeutic indexOrganic active ingredientsMacromolecular non-active ingredientsArgininePolyethylene glycol
The invention belongs to the technical field of biological medicines and relates to an integrin receptor-targeted taxol nanocomposite and a preparation method and application thereof. The preparation method comprises the following steps of: synthetizing a terminal carboxyl group-modified amphiphilic block copolymer HOOC-polyethylene glycol-poly trimethylene carbonate (HOOC-PEG-PTMC); connecting the amphiphilic block copolymer with a carboxyl group by an arginine-glycine-aspartic acid (RGD) polypeptide through an amido bond to obtain an RGD peptide-modified amphiphilic block copolymer; and introducing fat-soluble antitumor drug taxol into the amphiphilic block copolymer to prepare the integrin receptor-targeted taxol nanocomposite. Proved by an experimental result, the taxol nanocomposite can be used for increasing the drug concentration of the antitumor drug at a target part, reducing the accumulation of the antitumor drug at a non-target part and effectively increasing the treatment index of the drug. Shown by the result of an antitumor pharmacodynamic experiment, compared with a taxol control group, the taxol nanocomposite is more excellent in antitumor activity.
Owner:FUDAN UNIV
Delivery system for nucleic acids
InactiveUS7025987B2Accelerated destructionOrganic active ingredientsBiocideAmphiphileIntegrin antagonist
αvβ3 Integrin receptor targeting liposomes comprise a cationic amphiphile such as a cationic lipid, a neutral lipid, and a targeting lipid. The targeting lipid includes a non-peptidic αvβ3 integrin antagonist.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV +1
RGD/PTX-coated ZIF-90 drug delivery system and preparation method thereof
PendingCN112999352AIncreased release rateGood treatment effectOrganic active ingredientsPharmaceutical non-active ingredientsMetal-organic frameworkAdsorption effect
The invention discloses an RGD / PTX-coated ZIF-90 drug delivery system and a preparation method thereof, and belongs to the field of biological medicine. According to the drug delivery system, on the basis of the metal organic framework ZIF-90, aldehyde groups and amino groups of RGD are connected through a Schiff base reaction, PTX is entrapped through the adsorption effect, no extra chemical reagent is introduced in the whole process, and the drug delivery system is safer and more environmentally friendly. The preparation method is simple, the ZIF-90 and the RGD are stirred to obtain RGD / ZIF-90, then the RGD / ZIF-90 and the PTX are stirred together, and the RGD / PTX ZIF-90 composite material is obtained. According to the drug delivery system, aiming at the physiological characteristics of specific high expression of an alpha v beta 3 integrin receptor and low pH of tumor cells, RGD can target the tumor cells, and when the RGD reaches the vicinity of the tumor cells, the skeleton of ZIF-90 collapses, so that PTX is intensively released near the tumor cells, the anti-tumor activity is improved, the side effect of the drug can be reduced, and the drug delivery system has the advantages of strong anti-tumor effect, few side effects and high stability.
Owner:ANHUI UNIVERSITY OF TECHNOLOGY AND SCIENCE
Bionic recombined lipoprotein/photosensitizer nanoparticle, and preparation method and application of bionic recombined lipoprotein/photosensitizer nanoparticle in diagnosis and treatment
InactiveCN110179978AQuick releaseAchieve therapeutic effectPowder deliveryPhotodynamic therapyArginineFluorescence
The invention discloses a bionic recombined lipoprotein / photosensitizer nanoparticle, and a preparation method and an application of the bionic recombined lipoprotein / photosensitizer nanoparticle. Thenanoparticle comprises a phospholipid monomolecular layer, and a photosensitizer and cholesteryl ester that are enveloped in the phospholipid monomolecular layer, wherein RGD (arginine-glycine-aspartic acid) peptide modified apolipoprotein is embedded into the surface of the phospholipid monomolecular layer; and cholesterol is further distributed among phospholipid molecules of the phospholipid monomolecular layer. The nanoparticle is effectively accumulated at a tumor site through high permeability and a retention effect of a solid tumor and high affinity of the apolipoprotein and a scavenger receptor, and further achieves target deep penetration to the tumor using high affinity of RGD and an integrin receptor. The nanoparticle can generate active oxygen and high heat under irradiation of near infrared light, promotes quick release of the photosensitizer from lipoprotein, and achieves a synergic photodynamic and photo-thermal treatment effect; and at the same time, fluorescent lightgenerated by triggering of near-infrared wavelength light can effectively perform in-vivo diagnosis, so that the nanoparticle achieves double functions of target treatment and diagnosis.
Owner:CHINA PHARM UNIV
Agonists that enhance binding of integrin-expressing cells to integrin receptors
ActiveUS9512109B2High retention rateBiocideCarbamic acid derivatives preparationInvolucrinIntegrin Receptor
A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.
Owner:TEXAS HEART INST
Model for neurodegenerative diseases involving amyloid accumulation
The present invention provides brain cells, such as normal brain cells, apolipoprotein E deficient brain cells, or apoE4 containing brain cells, that are treated with a compound which can modulate integrins and / or integrin receptors to produce increased sequestration of and / or accumulation of and / or uptake of Aβ, and / or changes in cathepsin D content and / or lysosomal dysfunction, and / or microglia activation in the brain cells. The present invention also provides methods for producing such cells and methods for using the cells for screening an agent or substance that modulates the sequestration of and / or accumulation of and / or uptake of Aβ, and / or lysosomal dysfunction, and / or changes in cathepsin D content and / or microglia activation in the brain cells. The method further provides a new therapeutic target, antagonism of glutamate receptors, for the treatment of neurodegenerative diseases which are characterized by inter alia, abnormal amyloid uptake and / or accumulation.
Owner:RGT UNIV OF CALIFORNIA
Novel polypeptide with active tumor targeting and pH sensitive cell penetratingcapability
InactiveCN104497149AMediate efficientEfficient cell entryMacromolecular non-active ingredientsHybrid peptidesCyclic peptideTumor targeting
The invention provides a novel polypeptide which not only can be actively targeted to highly expressed integrin receptor of tumor cells, but also can efficiently mediate cell entry. The novel polypeptide TR(c(RGDfK)-AGYLLGHINLHHLAHL(Aib)HHIL-Cys) is formed by connecting cyclic RGD peptide (c(RGDfK)) of specificity-targeted integrin receptor and non-specific pH sensitive cell penetrating peptide TH(AGYLLGHINLHHLAHL(Aib)HHIL-Cys) through covalent bonds. The novel polypeptide TR is modified onto the surface of a drug carrier system, and can mediate the drug carrier system to more efficiently deliver to the inside of the tumor, so that the tumor can be more effectively treated.
Owner:SICHUAN UNIV
Multifunctional targeting gene vector as well as preparation method and application
InactiveCN108379595APromote escapeHigh transfection efficiencyGenetic material ingredientsPharmaceutical non-active ingredientsGene deliveryNuclear membrane
The invention discloses a multifunctional targeting gene vector as well as a preparation method and application. The multifunctional targeting gene vector is a polymer represented by P(LA-co-GA)-PEI-PEG-NLS-G-TAT-G-REDV; the multifunctional targeting gene vector disclosed by the invention has a membrane penetration function, a nuclear location function, and a targeting function on endothelial cells; cell extraction of a gene compound prepared from a multifunctional targeting polypeptide modified gene vector is improved through specific recognition of REDV peptide and an integrin receptor on the surfaces of the endothelial cells and the membrane penetration effect of TAT. The nuclear internalization of the gene is promoted through a mutual effect of a nuclear localization signal NLS and a nuclear membrane, so that a gene delivery effect is improved and the aims of improving the transfection efficiency and promoting cell migration and proliferation are realized. The problem of non-viralvectors at present is solved.
Owner:TIANJIN UNIV
Oriented collagen gel
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Composite exosome loaded with cRGD and small-molecule antitumor drug as well as preparation method and application of composite exosome
PendingCN114588274AImprove targetingLow toxicityOrganic active ingredientsPeptidesTumor targetStage melanoma
The invention relates to the technical field of pharmaceutical preparations, in particular to a composite exosome loaded with polypeptide and a small-molecule antitumor drug as well as a preparation method and application of the composite exosome. According to the composite exosome drug delivery system, exosome (Exosome, EXO) derived from human umbilical cord mesenchymal stem cells is used as a carrier, annular polypeptide cRGD is embedded on the membrane surface of the carrier so as to be delivered to melanoma cells with high expression of alpha v beta 3 integrin receptors in a targeted mode, small-molecule anti-tumor drugs are entrapped in the exosome membrane, and the drug delivery efficiency is improved. And constructing a composite exosome drug delivery system cRGD-EXO / small molecule antitumor drug. In-vivo and in-vitro experiments show that the drug delivery system has good tumor targeting property, and shows a remarkable tumor inhibition effect while reducing the toxic and side effects of the drug. The invention provides a small molecule drug delivery system which is good in targeting property, high in biological safety and exact in tumor inhibition effect for tumor treatment with high expression of an alpha v beta 3 integrin receptor.
Owner:FUDAN UNIV SHANGHAI CANCER CENT
Small-particle-size drug-loaded micelle for actively targeting alpha v beta 3 integrin receptor tumor cells and preparation method of small-particle-size drug-loaded micelle
InactiveCN110812492ASmall particle sizeGood biocompatibilityOrganic active ingredientsPharmaceutical non-active ingredientsSide effectIntegrin Receptor
The invention discloses a small-particle-size drug-loaded micelle for actively targeting alpha v beta 3 integrin receptor high-expression tumor cells and a preparation method of the small-particle-size drug-loaded micelle. The micelle comprises drug-loaded micelles, the surface of the drug-loaded micelle is modified by an alpha v beta 3 integrin receptor high-affinity ligand overexpressed on the surface of a tumor cell, aiming at the defects of insufficient targeting property and the like of antitumor drugs, a small-particle-size drug delivery system (the average particle size is about 15 nm)capable of targeting the high-expression tumor cells of the alpha v beta 3 integrin receptor is designed and constructed, PDI (0.2) is used for achieving the purposes that a medicine actively targetsspecific tumor cells and can be rapidly and effectively taken by the cells, the medicine effect of the medicine is brought into play to a greater extent, and the distribution of the medicine in the whole body and toxic and side effects caused by the distribution are reduced.
Owner:INNER MONGOLIA MEDICAL UNIV
Determining the effect of a substance on sequestration, uptake, and accumulation of amyloid in brain cells
InactiveUS7186521B2Avoiding characteristicApolipeptidesMicrobiological testing/measurementMicroglial cell activationLysosome
The present invention provides brain cells, such as normal brain cells, apolipoprotein E deficient brain cells, or apoE4 containing brain cells, that are treated with a compound which can modulate integrins and / or integrin receptors to produce increased sequestration of and / or accumulation of and / or uptake of Aβ, and / or changes in cathepsin D content and / or lysosomal dysfunction, and / or microglia activation in the brain cells. The present invention also provides methods for producing such cells and methods for using the cells for screening an agent or substance that modulates the sequestration of and / or accumulation of and / or uptake of Aβ, and / or lysosomal dysfunction, and / or changes in cathepsin D content and / or microglia activation in the brain cells. The method further provides a new therapeutic target, antagonism of glutamate receptors, for the treatment of neurodegenerative diseases which are characterized by inter alia, abnormal amyloid uptake and / or accumulation.
Owner:RGT UNIV OF CALIFORNIA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com